David A Westwood1, Oneel Patel2, Christopher Christophi2, Arthur Shulkes2, Graham S Baldwin2. 1. The University of Melbourne Department of Surgery, Austin Health, Heidelberg, Victoria, Australia. d.westwood@doctors.net.uk. 2. The University of Melbourne Department of Surgery, Austin Health, Heidelberg, Victoria, Australia.
Abstract
BACKGROUND AND AIMS: Staging of colorectal cancer often fails to discriminate outcomes of patients with morphologically similar tumours that exhibit different clinical behaviours. Data from several studies suggest that the gastrin family of growth factors potentiates colorectal cancer tumourigenesis. The aim of this study was to investigate whether progastrin expression may predict clinical outcome in colorectal cancer. METHODS: Patients with colorectal adenocarcinoma of identical depth of invasion who had not received neoadjuvant therapy were included. The patients either had stage IIa disease with greater than 3-year disease-free survival without adjuvant therapy or stage IV disease with liver metastases on staging CT. Progastrin expression in tumour sections was scored with reference to the intensity and area of immunohistochemical staining. RESULTS: Progastrin expression by stage IV tumours was significantly greater than stage IIa tumours with mean progastrin immunopositivity scores of 2.1 ± 0.2 versus 0.5 ± 0.2, respectively (P < 0.001). CONCLUSIONS: This is the first study to show that progastrin expression may be predictive of aggressive tumour behaviour in patients with colorectal cancer and supports its clinical relevance and potential use as a biomarker.
BACKGROUND AND AIMS: Staging of colorectal cancer often fails to discriminate outcomes of patients with morphologically similar tumours that exhibit different clinical behaviours. Data from several studies suggest that the gastrin family of growth factors potentiates colorectal cancer tumourigenesis. The aim of this study was to investigate whether progastrin expression may predict clinical outcome in colorectal cancer. METHODS:Patients with colorectal adenocarcinoma of identical depth of invasion who had not received neoadjuvant therapy were included. The patients either had stage IIa disease with greater than 3-year disease-free survival without adjuvant therapy or stage IV disease with liver metastases on staging CT. Progastrin expression in tumour sections was scored with reference to the intensity and area of immunohistochemical staining. RESULTS: Progastrin expression by stage IV tumours was significantly greater than stage IIa tumours with mean progastrin immunopositivity scores of 2.1 ± 0.2 versus 0.5 ± 0.2, respectively (P < 0.001). CONCLUSIONS: This is the first study to show that progastrin expression may be predictive of aggressive tumour behaviour in patients with colorectal cancer and supports its clinical relevance and potential use as a biomarker.
Authors: Catherine Do; Claudine Bertrand; Julien Palasse; Marie-Bernadette Delisle; Arthur Shulkes; Elizabeth Cohen-Jonathan-Moyal; Audrey Ferrand; Catherine Seva Journal: Cancer Prev Res (Phila) Date: 2012-02-24
Authors: Hanneke W M van Laarhoven; Johannes H A M Kaanders; Jasper Lok; Wenny J M Peeters; Paul F J W Rijken; Bastiaan Wiering; Theo J M Ruers; Cornelis J A Punt; Arend Heerschap; Albert J van der Kogel Journal: Int J Radiat Oncol Biol Phys Date: 2005-10-19 Impact factor: 7.038
Authors: Julie Giraud; Laura M Failla; Jean-Marc Pascussi; Ebba L Lagerqvist; Jérémy Ollier; Pascal Finetti; François Bertucci; Chu Ya; Imène Gasmi; Jean-François Bourgaux; Michel Prudhomme; Thibault Mazard; Imade Ait-Arsa; Leila Houhou; Daniel Birnbaum; André Pélegrin; Charles Vincent; James G Ryall; Dominique Joubert; Julie Pannequin; Frédéric Hollande Journal: Cancer Res Date: 2016-05-04 Impact factor: 12.701